Breakthrough-Therapy Designation The authors provide a perspective on the rationale and goals of the designation of “breakthrough therapy” by the Food and Drug Administration.
No takes yet. Share an insight, caveat, or question.
Corrigan‐Curay et al. (2018) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: